The journal Arthritis Research & Therapy has published the study Application of systems biology-based in silico tools to optimise treatment strategy identification in Still's disease carried out by Anaxomics Biotech, Novartis and the Münster University Children's Hospital using technology based on systems biology and artificial intelligence. 

Four biologic drugs (Anakinra, Canakinumab, Sarilumab and Tocilizumab) and two non-biologic drugs (Methotrexate and Prednisone) have been analysed.

Anaxomics' TPMS (Therapeutic Performance Mapping System) technology has made it possible to simulate patients with Still's disease or juvenile idiopathic arthritis treated with the drugs under study and to analyse the most efficient treatment. The conclusions pointed out that biologic drugs have a more direct action mechanism than non-biologic ones. The benefits of treatment with anti-IL1B in the early stages of the disease have also been identified.

The study was presented at the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) annual meeting.

Segú-Vergés, C; Coma, M; Kessel, C; Smeets, S; Foell, D; Aldea, A. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease. Arthritis Research & Therapy, 2021. https://doi.org/10.1186/s13075-021-02507-w

You may also be interested in:

• Oncotarget publishes study by ICO, Takeda, Anaxomics and UPF on brigatinib and alectinib to treat lung cancer
• Anaxomics inaugurates headquarters in Barcelona to continue growth in 2020
• Anaxomics artificial intelligence used for new malaria and diabetes studies